ORGANON ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Organon & Co. and Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for allegedly providing misleading statements regarding its capital allocation and dividend strategy, particularly following its acquisition of Dermavant [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Organon securities between October 31, 2024, and April 30, 2025 [1]. - Investors have until July 22, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations - Defendants allegedly made overwhelmingly positive statements while concealing material adverse facts about Organon's priorities, especially regarding capital allocation and debt reduction [3]. - The lawsuit highlights a significant reduction in the regular quarterly dividend by 70% due to the prioritization of debt reduction following the acquisition of Dermavant [3]. Group 3: Stock Price Impact - Following the news of the lawsuit, Organon's stock price dropped from $12.93 per share on April 30, 2025, to$9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [4].